Inhibrx is progressing its cancer treatments ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets. Ozekibart showed a 52% risk reduction in chondrosarcoma progression and strong responses in colorectal and Ewing sarcoma, leading to previous stock gains. INBRX-106 combined with Keytruda demonstrated promising results in head and neck cancer, especially in HPV+ patients. The FDA will decide on ozekibart's Biologics License Application by April 2027, with Inhibrx expanding Phase 2 trials for INBRX-106 aiming for accelerated approval in a $4 billion HPV+ head and neck cancer market and broader immunogenic tumor opportunities worth over $50 billion.
Remittix has raised $33 million and will burn 300 million RTX tokens, reducing supply by 20% ahead of public trading starting November 24, 2026. This token burn and near-cap funding boost scarcity and investor interest. Meanwhile, the XRP Ledger's No...
XTransfer, a leading global B2B cross-border payment platform, made its first appearance at Money20/20 USA 2026 in Las Vegas to accelerate its expansion into Latin American markets. The company recently completed regulatory registration in Chile, ena...
Kelvin Veras Real Estate completed 16 real estate transactions in its first year operating in New Jersey, including sales, purchases, rentals, and landlord services. This milestone highlights the company's successful market entry and diverse client s...
The documentary 'NURSE: Empathy Heals' premiered on October 21 in Nashville, showcasing personal stories of nurses and the critical role of empathy in healthcare. It highlights the emotional challenges nurses face, especially during crises like the C...
Oxford Square Capital Corp. announced it will hold a conference call on October 30, 2026, at 9:00 AM Eastern time to discuss its third quarter 2026 earnings. Investors can join the call via a toll-free number, and a recorded replay will be available ...
